Table 9.
Biological Evaluation of AIP Analogs and Amide Derivatives Thereofa
AgrC | ||||||
---|---|---|---|---|---|---|
Sequence | I | II | III* | IV | ||
331 | AIP-III | IN(CDFLL) | 5.05 | 5.63 | ag | 8.53 |
342 | AIP-III Amide | IN(XDFLL) | >1000 | >1000 | 75.2 | 299 |
335 | D4A | IN(CAFLL) | 0.485 | 0.429 | 0.0506 | 0.0349 |
343 | D4A Amide | IN(XAFLL) | 1.2 | 2.19 | 0.055 | 0.192 |
340 | tD2A | Ac(CAFLL) | 0.257 | 0.9 | 0.329 | 0.0957 |
344 | tD2A Amide | Ac(XAFLL) | 1.5 | 13.9 | 0.216 | 0.189 |
IC50 in nM, X = L-diaminopropionic acid, ag = agonist, t = truncated.
For the sake of comparison, x-fold improvement against AgrC-III is measured against the amide.